glp-1 and pancreas GLP-1: Actions on Beta-cell Mass Function Reconciling GLP-1s and Pancreatitis

The LR3 extension does not make it "safer" -- it makes it longer-acting and less regulated by binding proteins, which from a risk standpoint means sustained free IGF-1R activation without the IGFBP buffering system that modulates native IGF-1 activity in healthy physiology

This includes therapies in the autoimmune disease, oncology, emergency medicine and specialty injectables sectors

Neurological Support: May help with brain injury recovery and nerve regeneration

PMCID: PMC10146734

Application Considerations in Research: Start with a low concentration and frequency

Tirzepatide can complement these lifestyle modifications, providing individuals with the tools to achieve sustainable weight loss and maintain long-term glycemic control